Yaohui Wei

Dr. Yaohui Wei

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2022 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
YWYaohui Wei
Yaohui Wei
SPSufang Peng
Sufang Peng
CLCheng Lian
Cheng Lian
QKQing Kang
Qing Kang
JCJue Chen
Jue Chen
Host–microbiota interactions may be involved in many physical and psychological functions ranging from the digestion of food, maintenance of immune homeostasis, to the regulation of mood and cognit...

YWYaohui Wei
Yaohui Wei
ZLZhiqian Li
Zhiqian Li
LGLei Guo
Lei Guo
LZLei Zhang
Lei Zhang
CLCheng Lian
Cheng Lian
JCJue Chen
Jue Chen
COVID-19 has amplified long-standing emotional distress for vulnerable families. While abundant research highlights the importance of resilience under adverse circumstances, little has been undertaken to understand its effectiveness in helping caregivers of individuals with eating disorders (ED) navigate pandemic-related challenges. This paper presents findings of a cross-sectional study investigating the effects of COVID-19-related life disruptions (COLD) and COVID-19-related psychological distress (CORPD) on caregivers’ depression, anxiety and stress, as well as the moderation role of individual resilience (IR) and family resilience (FR) during the post-pandemic period in China. A total of 201 caregivers of individuals experiencing ED participated in our online survey from May 2022 to June 2022. The association between pandemic-related stressors (i.e., COLD and CORPD) and mental health conditions were confirmed. FR moderated the relationship between CORPD and mental health outcomes, while IR independently contributed to low emotional distress. We call for intervention programs strengthening caregivers’ FR and IR, which might benefit both patients and caregivers’ well-being in the post-pandemic period.

31 December 2024 in Foods
Verified
Journal Article
Open access
PDF file
YWYaohui Wei
Yaohui Wei
WYWang Yating
Wang Yating
YYYonggui Yuan
Yonggui Yuan
JCJue Chen
Jue Chen
Celiac disease (CD) and eating disorders (EDs) are complex chronic conditions in adolescents, sharing symptoms such as weight change, malnutrition, and gastrointestinal symptoms. CD, an autoimmune disorder triggered by gluten ingestion, is managed through a strict gluten-free diet that can unintentionally foster disordered eating behaviors due to dietary restrictions. Conversely, EDs may mask and complicate CD symptoms, leading to diagnostic delays and treatment challenges. Evidence reveals an increased risk of EDs in CD individuals and vice versa, indicating a potential bidirectional relationship. This review explores the mechanisms and clinical implications of this interplay and proposes integrated screening and care strategies to improve the quality of life for individuals with both conditions.

22 October 2025 in eClinicalMedicine
Verified
Journal Article
Open access
YWYaohui Wei
Yaohui Wei
CLCarolin Lorenz
Carolin Lorenz
SSSpyridon Siafis
Spyridon Siafis
JSJohannes Schneider-Thoma
Johannes Schneider-Thoma
DKDavid D. Kim
David D. Kim
SLStefan Leucht
Stefan Leucht
Non-invasive brain stimulation (NIBS) provides adjunctive therapeutic options for individuals with schizophrenia if medications are insufficient to produce clinical response, but guidelines remain controversial on whether NIBS is effective, and which NIBS methods and targets are preferred. We aimed to compare the efficacy and safety of NIBS for treatment-resistant schizophrenia (TRS). This systematic review and network meta-analysis of randomised controlled trials investigated NIBS interventions, including electroconvulsive therapy, magnetic seizure therapy (MST), repetitive transcranial magnetic stimulation (rTMS), and transcranial electric stimulation (tES), as adjunctive treatment for TRS. We searched the Cochrane Schizophrenia Group's specialised register from inception to 2025.07.13, and three Chinese databases from inception to 2024.10.30. The primary outcome was overall symptoms, and adverse events were analysed as secondary outcomes. We synthesized the data using random-effects network meta-analysis. Sensitivity analyses examined the robustness of the findings and the effects of the detailed NIBS protocols. The protocol was pre-registered with PROSPERO (CRD42023410645) and published in a scientific journal. We identified 21710 references and included 78 trials with a total of 3416 participants (1216 women, 1733 men; mean age 37.06 years, range 25.55–48.38; ethnicity data were not recorded). Compared with sham stimulation, rTMS (SMD −0.47, 95% CI [−0.62; −0.31]) was more efficacious in improving overall symptoms; but not in a sensitivity analysis excluding studies from Chinese mainland (−0.19, [−0.38; 0.01]). No clear differences between rTMS specific protocols in terms of stimulation targets and protocols were detected. No clear differences were found for electroconvulsive therapy (−0.20, [−0.78; 0.37]), tES (−0.08, [−0.38; 0.22]), and MST (−0.30, [−1.73; 1.13]) compared to sham stimulation. Treatment as usual might be less efficacious than sham (1.13, [−0.13; 2.38]), based on indirect evidence. NIBS was generally safe (rTMS produced headaches and local reactions), but information about adverse events was rarely reported. rTMS may be efficacious in individuals with TRS, but this finding was driven mainly by studies from Chinese mainland. No clear differences were observed for electroconvulsive therapy, tES, and MST, but the findings were imprecise and inconclusive. German 10.13039/501100002347 Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung/BMBF; 01KG2206).

21 May 2025 in Psychiatry Research
Verified
Journal Article
Closed access
ZZZheng Zhang
Zheng Zhang
WGWan-Jie Gu
Wan-Jie Gu
YWYaohui Wei
Yaohui Wei
SWSichu Wu
Sichu Wu
CWChun Wang
Chun Wang

22 May 2026 in eClinicalMedicine
Verified
Journal Article
Open access
YFYuki Furukawa
Yuki Furukawa
NSNurul Husna Salahuddin
Nurul Husna Salahuddin
YWYaohui Wei
Yaohui Wei
EPElisavet Pinioti
Elisavet Pinioti
DKDavid D. Kim
David D. Kim
SLStefan Leucht
Stefan Leucht
Antipsychotics are often insufficient for schizophrenia, but the optimal next-step strategies for non-response remain uncertain. Guidelines recommend some pharmacological, psychological, and non-invasive brain stimulation (NIBS) approaches, but we do not know which one works best. We summarized current evidence for schizophrenia non-responsive to antipsychotics. We searched the Cochrane Schizophrenia Group registry (up till January 13, 2025), and PubMed up till January 8, 2026 for randomized controlled trials (RCTs) of patients non-responsive to prior antipsychotic treatment, with persistent symptoms after at least one adequate 4-week antipsychotic trial. Raters needed to be masked. The primary outcome was change in overall symptoms analyzed using random-effects network meta-analyses of standardized mean differences (SMDs) with 95% confidence intervals (CIs). The protocol was pre-registered (https://osf.io/wcs5d/). Fifty-nine RCTs (5409 participants; mean age 39.8 years; 3416 men, 1441 women) were included; 5013 contributed to the primary analysis. Antipsychotic combination therapy (k = 18; n = 575; SMD −0.25, 95% CI −0.46 to −0.04; CINeMA: very low) and electroconvulsive therapy (ECT; k = 5; n = 97; SMD −0.51, −0.96 to −0.06; very low) might be more efficacious than continuing the same antipsychotic. Cognitive behavioral therapy for psychosis (CBTp) showed weak evidence of benefit over continuing the same antipsychotic (k = 5; n = 340; SMD −0.23, −0.58 to 0.11; very low). Other strategies—xanomeline–trospium augmentation, dose escalation, transcranial magnetic stimulation, and switching to clozapine or other antipsychotics—were inconclusive. Combination therapy increased adverse events (OR 1.93, 1.26–3.00). We found no evidence of subgroup difference among non-clozapine- and clozapine-non-response. The results were very uncertain. More head-to-head trials are needed. We found no evidence supporting dose-escalation nor switching to clozapine. Very weak evidence suggested efficacy of antipsychotic combination and ECT augmentation and they might be considered, but with substantial caution. This study was funded by the 10.13039/501100001659 German Research Foundation (DFG, #468853597) and the Federal Ministry of Research, Technology, and Space (BMTR, #01EE2303B), and partly by a grant from 10.13039/501100008667 SENSHIN Medical Research Foundation given to YF, DAAD fellowship to NHS and CSC scholarship to YHW.